Novartis | NOVN - Debt


Novartis reported $47B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Alcon AG USD 5.25B 4.74B Mar/2026
Almirall EUR 342.86M 61.94M Dec/2025
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Autolus Therapeutics Ltd USD 253.44M 8.84M Mar/2025
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Fresenius EUR 11.93B 919M Dec/2025
Fresenius Medical Care EUR 11.03B 233.8M Mar/2026
Genmab DKK 148M 5M Jun/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
GRIFOLS EUR 9.57B 746.56M Dec/2025
Hikma Pharmaceutical USD 1.56B 252M Jun/2025
J&J USD 47.93B 2.14B Dec/2025
Lakefront Biotherapeutics EUR 6.44M 480K Mar/2026
Lonza CHF 4.71B 915M Dec/2024
Merck EUR 11.95B 152M Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Novartis USD 47B 11.62B Mar/2026
Novartis USD 32.02B 615M Sep/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Orion EUR 305.4M 15.8M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
Philips EUR 7.81B 574M Dec/2025
Recordati EUR 2.47B 37.48M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 20.33B 1.43B Dec/2025
UCB EUR 3.03B 12M Dec/2024